Close
Nordic 9Nordic 9

E Ink (investor - Corporate Investor)

eink.com
See something wrong or missing? Let us know

E Ink is a developer of ePaper technology out of Taiwan

Average round investment:41.31M USD
Average number per year:1.5
Distribution: 2024 (2)2022 (1)
Portfolio companies: United Kingdom iFast DiagnosticsUnited Kingdom Nuclera
Mostly invests in: United Kingdom United Kingdom (3) Biotech (3)

3 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to E Ink

Name Criteria
United Kingdom Abingworth
73%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Walden Catalyst Ventures
73%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Petrichor Healthcare Capital Management
73%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Japan Ajinomoto
73%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Elevage Medical Technologies
73%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Michael D. McCreary
73%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
China Uni Power Group
73%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Canada CTI Life Sciences
73%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
China Hillhouse Capital Group
73%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.4
  • Active last 12 months: Yes
United States HOF Capital
73%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Top